All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
11 warning events since 2017; the latest 2026-05-22.
From the record
Tenon Medical, Inc.'s filings since 2017 show 11 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 10 times, the latest 2026-05-22); an auditor change (8-K item 4.01, the latest 2023-09-08) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+122.8% a year over 5 filed years; profitable in 0 of 3.
From the record
Tenon Medical, Inc.'s 5 filed years say what it did: revenue went from $160 thousand in fiscal 2021 to $4 million in fiscal 2025, up 122.8% a year; it rose in 4 of 4 years; it never fell from a peak; net income was positive in 0 of 3 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 0.1/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Tenon Medical, Inc.'s shareholder treatment is put at 0.1 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 1% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -249%: lost 249¢ per shareholder dollar. Leverage 53%: owes 53¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Tenon Medical, Inc. lost about 249 cents for every dollar of shareholders' money, and gross profitability: its products earned about 22 cents per dollar of everything the company owns. Leverage: it owed about 53 cents per dollar of assets, and net share issuance: its share count grew 508.2% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 41% of 109 in its family; net margin -318.4%.
From the record
Tenon Medical, Inc.'s standing among 109 graded names in its industry family: revenue of $4 million in fiscal 2025 ranks in the bottom 15% by size; a net margin of -318.4% ranks in the bottom 17%; revenue growth of 78.7% a year over the last 3 filed years ranks in the top 9% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 5.2/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Tenon Medical, Inc.'s leadership is put at 5.2 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 48% of 108 in its family; the record of its people begins on 2022-04-26 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 4.6 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
top 46% of 104 in its family for room to expand.
From the record
Tenon Medical, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $4 million against no long-term debt tagged leaves 34.9% of its assets as net cash, top 25% of its family; cash from operations less capital spending is -279.4% of revenue (bottom 14%); a gross margin of 59.8% (bottom 47%); research spending of 54.5% of revenue (top 20%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 28% of 105 in its family for growth drivers.
From the record
Tenon Medical, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 78.7% a year over the last three filed years against 122.8% over all 5, slowing (bottom 5% of its family); the newest year grew 20.4% (top 30%); research spending grew -8.7% a year (bottom 20%); capital spending grew -31.4% a year (bottom 17%) (its annual reports). Tenon Medical, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 48% of 88 in its family for expectations against reality.
From the record
Tenon Medical, Inc.'s newest year against its own record: revenue of $4 million in fiscal 2025 came in 44.7% below the $7 million its prior three years' pace pointed to (bottom 7% of its family); net income of $13 million against a prior three-year average of $15 million (bottom 49%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 12%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made